A single centre, placebo-controlled, four period, crossover, tolerability study assessing, pharmacodynamic effects, pharmacokinetic characteristics and cognitive profiles of a single dose of three formulations of Cannabis Based Medicine Extracts (CBMEs) (GWPD9901), (see abstract)

Journal of Cannabis Therapeutics

Volumn 3, Issue 3, 2003, Pages 35-77

  Guy, G W ^a   Flint, M E ^a  

^a Porton Down Science Park   (United Kingdom)

Author keywords

Alternative delivery systems; Botanical extracts; Cannabidiol; Cannabinoids; Cannabis; Harm reduction; Medical marijuana; Multiple sclerosis; Pharmacodynamics; Pharmacokinetics; THC

Indexed keywords

CANNABIDIOL; CANNABIS; CANNABIS DERIVATIVE; CREMOPHOR; FLAVORING AGENT; GLYCEROL; GW 1009 01; GW 1011 01; GW 1012 01; GW 2009 01; GW 3009 01; LAURYL ALCOHOL; MACROGOL; PARACETAMOL; PEPPERMINT; PLACEBO; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; VITAMIN;

ABDOMINAL PAIN; ADULT; AEROSOL; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CLINICAL STUDY; CLINICAL TRIAL; COGNITION; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DEMOGRAPHY; DEPRESSION; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG MIXTURE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ELECTROCARDIOGRAPHY; EXPERIMENTAL DESIGN; FEMALE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; LABORATORY TEST; LOUDNESS RECRUITMENT; MALE; MEDICAL ASSESSMENT; MEDICINAL PLANT; MOOD DISORDER; NEBULIZER; NORMAL HUMAN; PALLOR; PATIENT COMPLIANCE; PATIENT SELECTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SINGLE DRUG DOSE; SLEEP DISORDER; STATISTICAL SIGNIFICANCE; SWEAT GLAND DISEASE; TACHYCARDIA; UNPLEASANT DREAM; URINALYSIS; WAKEFULNESS; WELLBEING; XEROSTOMIA;

EID: 1242322505     PISSN: 15299775     EISSN: None     Source Type: Journal    
DOI: 10.1300/J175v03n03_03     Document Type: Article

References (10)

1. Agurell, S., M. Halldin, J. E. Lindgren, A. Ohlsson, M. Widman, H. Gillespie, and L. Hollister. 1986. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38 (1):21-43.
2. British Medical Association. 1997. Therapeutic uses of cannabis. Amsterdam: Harwood Academic Publishers.
3. Baker, P. B., T. A. Gough, and B. J. Taylor. 1983. The physical and chemical features of Cannabis plants grown in the United Kingdom of Great Britain and Northern Ireland from seeds of known origin-Part II: Second generation studies. Bull Narc 35 (1):51-62.
4. GW Pharmaceuticals. 2002. Investigators brochure for cannabis based medicine extract (CBME). Porton Down: GW Pharmaceuticals.
5. House of Lords. 1998. Cannabis: The scientific and medical evidence. London: House of Lords Select Committee on Science and Technology, Stationery Office.
6. Maykut, M. O. 1985. Health consequences of acute and chronic marihuana use. Prog Neuropsychopharmacol Biol Psychiatry 9 (3):209-38.
7. McPartland, J. M., and E. B. Russo. 2001. Cannabis and cannabis extracts: Greater than the sum of their parts? J Cannabis Therapeutics 1 (3-4):103-132.
8. Portenoy, R. K. 1990. Chronic opioid therapy in nonmalignant pain. J Pain Symptom Manage 5 (1 Suppl):S46-62.
9. Porter, J., and H. Jick. 1980. Addiction rare in patients treated with narcotics. N Engl J Med 302 (2):123.
10. Whittle, B. A., G. W. Guy, and P. Robson. 2001. Prospects for new cannabis-based prescription medicines. J Cannabis Therapeutics 1 (3-4):183-205.